Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit.
Nickles E, Dharmadhikari B, Yating L, Walsh RJ, Koh LP, Poon M, Tan LK, Wang LZ, Ang Y, Asokumaran Y, Chong WQ, Huang Y, Loh KS, Tay J, Soo R, Koh M, Ho LP, Chan M, Niam M, Soh M, Luah YH, Lim CM, Kaliaperumal N, Au VB, Talib NBSN, Sng R, Connolly JE, Goh BC, Schwarz H.
Nickles E, et al. Among authors: ho lp.
Cancer Immunol Immunother. 2022 Jun;71(6):1531-1543. doi: 10.1007/s00262-021-03075-3. Epub 2021 Oct 18.
Cancer Immunol Immunother. 2022.
PMID: 34661709
Free PMC article.
Clinical Trial.